Astellas Shuts U.S./EU Phase III Trial But Resumes Asia Development For Differentiated Markets
This article was originally published in PharmAsia News
Executive Summary
Astellas’ multi-track R&D approach leaves door open for a western partner interested in a Phase III SGLT2 inhibitor, but the Japanese pharma’s main interest is finding ipragliflozin’s niche in Asia.